Dorothea Gadzicki

Summary

Affiliation: Hannover Medical School
Country: Germany

Publications

  1. ncbi Common breast cancer susceptibility alleles are associated with tumour subtypes in BRCA1 and BRCA2 mutation carriers: results from the Consortium of Investigators of Modifiers of BRCA1/2
    Anna Marie Mulligan
    Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge, 2 Worts Causeway, Cambridge, CB1 8RN, UK
    Breast Cancer Res 13:R110. 2011
  2. ncbi Jacobsen syndrome and Beckwith-Wiedemann syndrome caused by a parental pericentric inversion inv(11)(p15q24)
    D Gadzicki
    Institute of Cell and Molecular Pathology, Hannover Medical School, Carl Neuberg Strasse 1, 30625 Hannover, Germany
    Ann Hum Genet 70:958-64. 2006
  3. ncbi Histopathological criteria and selection algorithms for BRCA1 genetic testing
    Dorothea Gadzicki
    Institute of Cell and Molecular Pathology, Hannover Medical School, Carl Neuberg Str 1, 30625 Hannover, Germany
    Cancer Genet Cytogenet 189:105-11. 2009
  4. ncbi Fluorescence in situ hybridization reveals closely correlated results in cytological and histological specimens of hematological neoplasias compared to conventional cytogenetics
    Heidrun Gerr
    Institute of Cell and Molecular Pathology, Hannover Medical School, Hannover, Germany
    Pathobiology 73:271-9. 2006
  5. ncbi Recurrent involvement of heterochromatic regions in multiple myeloma-a multicolor FISH study
    Kathrin Lange
    Institute of Cell and Molecular Pathology, Hannover Medical School, Carl Neuberg Str 1, 30625 Hannover, Germany
    Leuk Res 34:1002-6. 2010
  6. ncbi Standardised fluorescence in situ hybridisation in cytological and histological specimens
    Ludwig Wilkens
    Institute of Cell and Molecular Pathology, Hannover Medical School, Carl Neuberg Str 1, 30625 Hannover, Germany
    Virchows Arch 447:586-92. 2005
  7. ncbi BCR-ABL gene amplification and overexpression in a patient with chronic myeloid leukemia treated with imatinib
    Dorothea Gadzicki
    Institute of Cell and Molecular Pathology, Hannover Medical School, Carl-Neuberg-Str. 1, 30625 Hannover, Germany
    Cancer Genet Cytogenet 159:164-7. 2005
  8. ncbi Comprehensive genetic and functional characterization of IPH-926: a novel CDH1-null tumour cell line from human lobular breast cancer
    Matthias Christgen
    Institute of Pathology, Hannover Medical School, 30625 Hannover, Germany
    J Pathol 217:620-32. 2009
  9. ncbi Breast cancer susceptibility: current knowledge and implications for genetic counselling
    Tim Ripperger
    Institute of Cell and Molecular Pathology, Hannover Medical School, Hannover, Germany
    Eur J Hum Genet 17:722-31. 2009
  10. ncbi No evidence for breast cancer susceptibility associated with variants of BRD7, a component of p53 and BRCA1 pathways
    Judith Penkert
    Institute of Cell and Molecular Pathology, Hannover Medical School, Carl Neuberg Strasse 1, Hannover, Germany
    Fam Cancer 11:601-6. 2012

Collaborators

  • Brigitte Schlegelberger
  • Doris Steinemann
  • L Wilkens
  • Ulrich Lehmann
  • Alfons Meindl
  • Britta Hasemeier
  • Matthias Christgen
  • Jorg Schmidtke
  • Matthias Ballmaier
  • C Klein
  • Brigitte Pabst
  • A Baumer
  • Manfred Stuhrmann
  • Aristoteles A N Giagounidis
  • Judith Penkert
  • Anna Marie Mulligan
  • Gudrun Göhring
  • Kathrin Lange
  • Kathrin Wessels
  • Tim Ripperger
  • Heidrun Gerr
  • Christian F Singer
  • Marie Stenmark-Askmalm
  • Rosa B Barkardottir
  • Jenny Gross
  • Mark Robson
  • Mark Sherman
  • Maroulio Pertesi
  • Georgia Chenevix-Trench
  • Pascaline Berthet
  • Siranoush Manoukian
  • Barbara Pasini
  • Martine Dumont
  • Esther M John
  • Olufunmilayo Olopade
  • Yuan Chun Ding
  • Ute Hamann
  • von Anna Wachenfeldt
  • Wolfram Heinritz
  • Kenneth Offit
  • Torben A Kruse
  • Susan J Ramus
  • Laura Papi
  • Thomas vO Hansen
  • Fergus J Couch
  • Mark H Greene
  • Jeffrey N Weitzel
  • Daniel Barrowdale
  • Julian Barwell
  • Hilmi Ozcelik
  • Julian Adlard
  • Isabelle Mortemousque
  • Sylvie Mazoyer
  • Vernon S Pankratz
  • David Goldgar
  • Michel Longy
  • Debra Frost
  • Marcel R Nelen
  • Xianshu Wang
  • Anneliese Fink-Retter
  • Daphne Gschwantler-Kaulich
  • Susan L Neuhausen
  • Csilla Szabo
  • Paolo Radice
  • Irene L Andrulis
  • Dieter Niederacher
  • Christoph Engel
  • Hanne E J Meijers-Heijboer
  • Nicolas Sevenet
  • Stephen Fox
  • Uffe Birk Jensen
  • Norbert Arnold
  • Helen Gregory
  • Madeleine M A Tilanus-Linthorst
  • Wendy Chung
  • Trinidad Caldes
  • Andrew Lee
  • Caroline Seynaeve
  • Noah Kauff
  • Karin Kast
  • Gordon Glendon
  • Daniela Zaffaroni
  • Barbara Wappenschmidt
  • Silvia Tognazzo
  • Caroline Kientz
  • Bernardo Bonanni
  • Dieter Schäfer
  • Per Karlsson
  • Francois Cornelis
  • Olga M Sinilnikova

Detail Information

Publications12

  1. ncbi Common breast cancer susceptibility alleles are associated with tumour subtypes in BRCA1 and BRCA2 mutation carriers: results from the Consortium of Investigators of Modifiers of BRCA1/2
    Anna Marie Mulligan
    Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge, 2 Worts Causeway, Cambridge, CB1 8RN, UK
    Breast Cancer Res 13:R110. 2011
    ..It is currently unknown how these alleles are associated with different breast cancer subtypes in BRCA1 and BRCA2 mutation carriers defined by estrogen (ER) or progesterone receptor (PR) status of the tumour...
  2. ncbi Jacobsen syndrome and Beckwith-Wiedemann syndrome caused by a parental pericentric inversion inv(11)(p15q24)
    D Gadzicki
    Institute of Cell and Molecular Pathology, Hannover Medical School, Carl Neuberg Strasse 1, 30625 Hannover, Germany
    Ann Hum Genet 70:958-64. 2006
    ....
  3. ncbi Histopathological criteria and selection algorithms for BRCA1 genetic testing
    Dorothea Gadzicki
    Institute of Cell and Molecular Pathology, Hannover Medical School, Carl Neuberg Str 1, 30625 Hannover, Germany
    Cancer Genet Cytogenet 189:105-11. 2009
    ..001 for G3), ER negativity (P = 0.0075), Ki67 > or = 65% (P = 0.0039), and triple negativity (i.e., ER(-), PR(-), Her2/neu(-)) (P = 0.0019) between tumors of mutation carriers and noncarriers...
  4. ncbi Fluorescence in situ hybridization reveals closely correlated results in cytological and histological specimens of hematological neoplasias compared to conventional cytogenetics
    Heidrun Gerr
    Institute of Cell and Molecular Pathology, Hannover Medical School, Hannover, Germany
    Pathobiology 73:271-9. 2006
    ..Therefore, the use of biopsy sections for the routine FISH examination of chromosomal abnormalities is a valid method...
  5. ncbi Recurrent involvement of heterochromatic regions in multiple myeloma-a multicolor FISH study
    Kathrin Lange
    Institute of Cell and Molecular Pathology, Hannover Medical School, Carl Neuberg Str 1, 30625 Hannover, Germany
    Leuk Res 34:1002-6. 2010
    ..These chromosome aberrations were generated by breaks in heterochromatic regions indicating an increased breakage of these regions, which may predispose to the generation of chromosome aberrations in multiple myeloma...
  6. ncbi Standardised fluorescence in situ hybridisation in cytological and histological specimens
    Ludwig Wilkens
    Institute of Cell and Molecular Pathology, Hannover Medical School, Carl Neuberg Str 1, 30625 Hannover, Germany
    Virchows Arch 447:586-92. 2005
    ..The protocol shown here is easy to perform and can be used with cytological and histological specimens. Moreover, with "hands on" time of less than 2 h, FISH can also be used for daily routine purposes...
  7. ncbi BCR-ABL gene amplification and overexpression in a patient with chronic myeloid leukemia treated with imatinib
    Dorothea Gadzicki
    Institute of Cell and Molecular Pathology, Hannover Medical School, Carl-Neuberg-Str. 1, 30625 Hannover, Germany
    Cancer Genet Cytogenet 159:164-7. 2005
    ..We give further evidence that the genomic BCR-ABL amplification results in an increased level of BCR-ABL transcript linking two potent mechanisms of resistance against imatinib treatment...
  8. ncbi Comprehensive genetic and functional characterization of IPH-926: a novel CDH1-null tumour cell line from human lobular breast cancer
    Matthias Christgen
    Institute of Pathology, Hannover Medical School, 30625 Hannover, Germany
    J Pathol 217:620-32. 2009
    ..In summary, IPH-926 significantly extends the biological spectrum of the established breast cancer cell lines and will facilitate functional analyses of genuine human ILBC cells in vitro and in vivo...
  9. ncbi Breast cancer susceptibility: current knowledge and implications for genetic counselling
    Tim Ripperger
    Institute of Cell and Molecular Pathology, Hannover Medical School, Hannover, Germany
    Eur J Hum Genet 17:722-31. 2009
    ....
  10. ncbi No evidence for breast cancer susceptibility associated with variants of BRD7, a component of p53 and BRCA1 pathways
    Judith Penkert
    Institute of Cell and Molecular Pathology, Hannover Medical School, Carl Neuberg Strasse 1, Hannover, Germany
    Fam Cancer 11:601-6. 2012
    ..However, further analyses in larger cohorts of women with hereditary breast cancer should clarify the role of BRD7 in breast cancer predisposition...
  11. ncbi Novel CHD7 mutations contributing to the mutation spectrum in patients with CHARGE syndrome
    Kathrin Wessels
    Institute of Human Genetics, Hannover Medical School, Hannover, Germany
    Eur J Med Genet 53:280-5. 2010
    ..The mutation detection rate in this study was 44.4% in patients with a clinically established or suspected diagnosis of CHARGE syndrome...
  12. ncbi Tourette syndrome is not caused by mutations in the central cannabinoid receptor (CNR1) gene
    Dorothea Gadzicki
    Institute of Human Genetics, Hannover Medical School, Hannover, Germany
    Am J Med Genet B Neuropsychiatr Genet 127:97-103. 2004
    ..We conclude that genetic variations of the CNR1 gene are not a plausible explanation for the clinically observed relation between the cannabinoid system and TS...